Publicacións nas que colabora con Francisco Javier Burgos Revilla (6)

2023

  1. Clinical Usefulness of Prostate-specific Membrane Antigen-ligand Positron Emission Tomography/Computed Tomography for the Detection of Prostate Cancer Biochemical Recurrence after Primary Radiation Therapy in Patients with Prostate-specific Antigen Below the Phoenix Threshold: Systematic Review and Meta-analysis

    Clinical Oncology, Vol. 35, Núm. 12, pp. e676-e688

  2. Long-term Recurrence and Progression Patterns in a Contemporary Series of Patients with Carcinoma In Situ of the Bladder With or Without Associated Ta/T1 Disease Treated with Bacillus Calmette-Guérin: Implications for Risk-adapted Follow-up

    European Urology Focus, Vol. 9, Núm. 2, pp. 325-332

  3. Oncological and Renal Function Outcomes in Patients Who Underwent Simultaneous Radical Cystectomy and Nephroureterectomy for Synchronous or Metachronous Panurothelial Carcinoma

    Urology, Vol. 172, pp. 157-164

2022

  1. Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high–grade non-muscle-invasive urothelial bladder cancer

    Urologic Oncology: Seminars and Original Investigations, Vol. 40, Núm. 11, pp. 491.e11-491.e19

  2. Corrigendum to <‘Mitomycin C allergy after passive and device-assisted hyperthermia for non-muscle invasive bladder cancer treatment: A retrospective cohort from a high-volume center’> <[Volume 40, Issue 7, July 2022, Pages 345.e19-345.e23]> (Urologic Oncology: Seminars and Original Investigations (2022) 40(7) (345.e19–345.e23), (S1078143922000679), (10.1016/j.urolonc.2022.02.018))

    Urologic Oncology: Seminars and Original Investigations

  3. Mitomycin C allergy after passive and device-assisted hyperthermia for non-muscle invasive bladder cancer treatment: A retrospective cohort from a high-volume center

    Urologic Oncology: Seminars and Original Investigations, Vol. 40, Núm. 7, pp. 345.e19-345.e23